ArticleEmerging infectious diseases2021
Shiga Toxin-Associated Hemolytic Uremic Syndrome in Adults, France, 2009-2017.
Article in Emerging infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review.Pediatric nephrology (Berlin, Germany) · 2024Pooled it
- Post-Infectious Sequelae Following a Shiga Toxin-ProducingOpen forum infectious diseases · 2026Article
- A Monolithic, Thiol-Functionalized Au-Based Bio-CMOS Aptasensor for Rapid, Label-Free Detection ofBioengineering (Basel, Switzerland) · 2026Article
- Article
- Hemolytic Uremic Syndrome Outbreak in Adults and Shiga Toxin-Producing Escherichia coli Negative for Locus of Enterocyte Effacement, France, 2025.Emerging infectious diseases · 2026Article
- Article
- Virulence genes, antimicrobial resistance profiles and phylogroups of Shiga toxin-producing Escherichia coli and atypical enteropathogenic Escherichia coli isolates from dairy cattle in South Africa.World journal of microbiology & biotechnology · 2025Article
- Shiga Toxin-ProducingKidney international reports · 2025Article
- Shiga toxin-producingMicrobiology and molecular biology reviews : MMBR · 2025Review
- Two cases of typical HUS in adults treated with an anti-C5 monoclonal antibody: a new perspective?Journal of nephrology · 2025Article
- A prophage encoded ribosomal RNA methyltransferase regulates the virulence of Shiga-toxin-producing Escherichia coli (STEC).Nucleic acids research · 2024Article
- Diagnosis and Treatment for Shiga Toxin-ProducingToxins · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted a retrospective study on hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli (STEC) in 96 adults enrolled in the cohort of the National Reference Center for Thrombotic Microangiopathies network in France during 2009-2017. Most infections were caused by STEC strains not belonging to the O157 or O104 serogroups. Thirty (31.3%) patients had multiple risk factors for thrombotic microangiopathy. In total, 61 (63.5%) patients required dialysis, 50 (52.1%) had a serious neurologic complication, 34 (35.4%) required mechanical ventilation, and 19 (19.8%) died during hospitalization. We used multivariate analysis to determine that the greatest risk factors for death were underlying immunodeficiency (hazard ratio 3.54) and severe neurologic events (hazard ratio 3.40). According to multivariate analysis and propensity score-matching, eculizumab treatment was not associated with survival. We found that underlying conditions, especially immunodeficiency, are strongly associated with decreased survival in adults who have hemolytic uremic syndrome caused by STEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.